STOCK TITAN
  1. Home
  2. News
  3. BGNE

BeiGene Ltd - BGNE STOCK NEWS

Welcome to our dedicated news page for BeiGene (Ticker: BGNE), a resource for investors and traders seeking the latest updates and insights on BeiGene.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BeiGene's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BeiGene's position in the market.

News
BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
Rhea-AI Summary
BeiGene, Ltd. (BGNE) reports a remarkable year with record revenues, strong hematology leadership, and innovative pipeline progress. The company achieved total revenues of $634 million in Q4 and $2.5 billion in 2023, marking a 67% and 74% increase from the previous year. Key highlights include the success of BRUKINSA, initiation of registrational trials for sonrotoclax, and expansion of the hematology pipeline. Financially, product revenues surged by 86% in Q4 and 75% in 2023, driven by BRUKINSA and tislelizumab sales. Operating expenses increased due to R&D investments, but net loss improved, supported by reduced operating losses. The company's regulatory progress and development programs show promising milestones ahead, reinforcing its position as a global oncology leader.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.33%
Tags
earnings
-
News
BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
Rhea-AI Summary
BeiGene's tislelizumab receives positive CHMP opinion for NSCLC treatment after successful Phase 3 trials, showing efficacy in treatment-naïve and treatment-resistant patients. The drug is recommended for various NSCLC indications, including as a first- and second-line therapy, with promising results published in reputable medical journals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.33%
Tags
none
-
News
BeiGene Welcomes Experienced Life Sciences Executive Olivier Brandicourt to Board of Directors
Rhea-AI Summary
BeiGene, Ltd. (NASDAQ: BGNE) appoints Olivier Brandicourt, M.D. to its Board of Directors, replacing Thomas Malley. Dr. Brandicourt brings global pharmaceutical and medical leadership experience, aiming to advance the company's mission to bring innovative cancer medicines to more patients around the world.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.61%
Tags
management
News
FDA Approves Label Update for BRUKINSA® (zanubrutinib) in Chronic Lymphocytic Leukemia (CLL)
Rhea-AI Summary
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) announces U.S. label update for BRUKINSA® (zanubrutinib) to include superior progression-free survival results from the Phase 3 ALPINE trial compared to IMBRUVICA® (ibrutinib) in Relapsed or Refractory CLL.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
fda approval
-
News
BeiGene to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
BeiGene, Ltd. (BGNE) to participate in the 42nd Annual J.P. Morgan Healthcare Conference with a presentation on January 8th, 2024. The live webcast can be accessed from the investors section of BeiGene’s website with archived replays available for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.05%
Tags
conferences
-
News
BeiGene to Host ASH Investor Meeting in Person and via Webcast on December 10, 2023
Rhea-AI Summary
BeiGene, Ltd. (BGNE) to host Investor Event at ASH Annual Meeting and Exposition to cover R&D progress and hematology portfolio
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.08%
Tags
conferences
News
BeiGene to Present New Data Highlighting Hematology Portfolio and Pipeline Strengths at ASH 2023
Rhea-AI Summary
BeiGene, a global biotechnology company (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), announced positive results from ongoing studies and trials at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition. The data showcases the potential of BRUKINSA as a best-in-class BTK inhibitor and promising clinical advances across their pipeline, including the BCL2 inhibitor sonrotoclax and BTK degrader BGB‑16673.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.03%
Tags
conferences
-
News
BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor
Rhea-AI Summary
BeiGene (BGNE) acquires an exclusive global license to an Investigational New Drug (IND) application-ready oral cyclin-dependent kinase 2 (CDK2) inhibitor from Ensem Therapeutics, Inc. The agreement involves an upfront payment and potential additional payments of up to $1.33 billion, along with tiered royalties. This partnership strengthens BeiGene's early development pipeline in breast cancer and other solid tumors, complementing their internally discovered Phase 1 CDK4 inhibitor. Ensem will work with BeiGene to bring this molecule into the clinic in the near future, aiming to transform the therapeutic landscape for cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
partnership
-
News
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma
Rhea-AI Summary
BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160; SSE: 688235) announced that the European Commission granted marketing authorization for BRUKINSA® (zanubrutinib) in combination with obinutuzumab for the treatment of adult patients with relapsed or refractory follicular lymphoma. This is the fourth indication in the EU for BRUKINSA, making it the first and only BTK inhibitor approved for follicular lymphoma in the European Union, with the broadest label of any medicine in its class globally. The approval was based on results from the ROSEWOOD trial, where BRUKINSA plus obinutuzumab achieved a higher overall response rate compared to obinutuzumab alone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.21%
Tags
none
News
BeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates
Rhea-AI Summary
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) reported $781 million in total revenue and $595 million in global product sales for the third quarter of 2023, reflecting a 102% and 70% increase from the prior-year period, respectively. Key highlights include the approval of TEVIMBRA in the EU for 2L esophageal squamous cell carcinoma (ESCC) and the acceptance for review of a Biologics License Application (BLA) for tislelizumab as a first-line treatment for patients with ESCC in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.04%
Tags
earnings
Stock BGNE logo
BeiGene Ltd

Nasdaq:BGNE

BGNE Rankings

#621 Ranked by Market Cap
#1946 Ranked by Stock Gains
N/A Ranked by Dividends

BGNE Stock Data

14.97B
762.01M
0.03%
48.09%
1.65%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
China (Mainland)
Changping District

About BGNE

BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib.